With its AI platform, Dyno generates an unprecedented diversity of viral vectors to amplify the range of diseases treatable with genetic medicines.
A model of Dyno Therapeutics’ adeno-associated virus (AAV) capsid with all monomers assembled. The company’s CapsidMap™ platform rapidly discovers and systematically optimizes AAV capsids that significantly outperform current in vivo gene delivery approaches, thereby increasing the scope of diseases treatable with gene therapies. [Dyno Therapeutics]
Dyno Therapeutics — named after the high-risk, high reward mountaineering maneuver where an intrepid climber jumps or swings to the next hold, letting go of all contact points — is pioneering an artificial intelligence (AI)-powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, Dyno Therapeutics is inventing new ways to design viral vectors by focusing on cell-targeting capsid proteins from AAVs . . .
